-
1
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the...
Published 2024-10-01“…Drugs - Real World Outcomes…”
Get full text
Article